ICH = 2 Years after last approval based on study [Regulatives / Guidelines]

posted by Ohlbe – France, 2020-09-01 13:03 (885 d 05:52 ago) – Posting: # 21906
Views: 1,693

Dear Brus,

❝ 2 Years for ICH? Where did you find that?


In ICH E6 (GCP), § 4.9.5:

Essential documents should be retained until at least 2-years after the last approval of a marketing application in an ICH region and until there are no pending or contemplated marketing applications in an ICH region or at least 2-years have elapsed since the formal discontinuation of clinical development of the investigational product. These documents should be retained for a longer period however if required by the applicable regulatory requirements or by an agreement with the sponsor.

Cave: not 2 years after the end of the study, but 2 years after the last approval based on that study.

Regards
Ohlbe

Complete thread:

UA Flag
Activity
 Admin contact
22,478 posts in 4,708 threads, 1,604 registered users;
15 visitors (0 registered, 15 guests [including 10 identified bots]).
Forum time: 17:55 CET (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5